The $300 million biotech firm has received lots of attention recently due to its unapproved drug TKM-Ebola, a treatment for the deadly virus ravaging people in West Africa.
"Earlier this month, the [U.S. Food and Drug Administration] put a hold on a Tekmira Pharmaceuticals Corp clinical trial of TKM-Ebola, one of the few Ebola treatments advanced enough to be tested in people," reported Reuters' Julie Steenhuysen.
The stock has been trading in a wide range in recent weeks, swinging between $5.08 and $31.48 in the past year.
Shares closed at $14.23, up 6.5% for the day.